Granisetron plus dexamethasone may increase arrhythmia risk
the ONA take:
According to two studies published online ahead of print in the journal BMC Medicine, researchers have found that granisetron, a serotonin 5HT3 receptor antagonist, plus dexamethasone may increase a patient's risk for developing an arrhythmia.
Most arrhythmias are no serious; however, some put patients at a higher risk for stroke, heart failure, or cardiac arrest.
Serotonin receptor antagonists, such as granisetron, ondansetron, and palonosetron, are commony used to reduce nausea and vomiting in patients receiving moderately or highly emetogenic chemotherapy, as well as in those undergoing surgery.
Results of the studies showed that the safest serotonin receptor antagonists in combination with a steroid with respect to arrhythmia were ondansetron plus dexamethasone, and dolasetron for patients of all ages.
The studies were conducted in patients undergoing anesthesia for surgery.
Granisetron plus dexamethasone may increase a patient's risk for developing an arrhythmia.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|